KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Interest Expenses (2016 - 2022)

NovoCure (NVCR) has disclosed Interest Expenses for 9 consecutive years, with $2.2 million as the latest value for Q2 2022.

  • Quarterly Interest Expenses rose 137.02% to $2.2 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Mar 2023, down 67.26% year-over-year, with the annual reading at $7.7 million for FY2021, 37.05% down from the prior year.
  • Interest Expenses hit $2.2 million in Q2 2022 for NovoCure, up from $1.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $4.9 million in Q1 2018 to a low of $940000.0 in Q2 2021.
  • Historically, Interest Expenses has averaged $2.5 million across 5 years, with a median of $2.4 million in 2018.
  • Biggest five-year swings in Interest Expenses: tumbled 64.08% in 2021 and later skyrocketed 137.02% in 2022.
  • Year by year, Interest Expenses stood at $2.2 million in 2018, then dropped by 19.21% to $1.7 million in 2019, then skyrocketed by 87.22% to $3.3 million in 2020, then tumbled by 33.43% to $2.2 million in 2021, then rose by 2.44% to $2.2 million in 2022.
  • Business Quant data shows Interest Expenses for NVCR at $2.2 million in Q2 2022, $1.7 million in Q1 2022, and $2.2 million in Q4 2021.